Ischemia Modified Albumin as an Acute - Phase Reactant

mean concentration of 0.63 mmol/L, is a powerful acute phase reactant as it changes dramatically during vascular injury and inflammatory processes5. Albumin acts as a buffering agent for endogenous or exogenous toxic molecules due to its various ligands binding ability4,5. The biochemical mechanisms modifying the amino-terminal region of albumin during ischemia are unclear, but reperfusion after an ischemic event may damage serum albumin as much as, if not more than, ischemia itself 6,7. Accumulating evidence support that IMA is also produced in the clinical setting of ischemia-reperfusion conditions with excessive oxidative stress state, like those observed in thrombolytic therapy, coronary intervention and open-heart surgery8,9.